Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Receivables (2023 - 2025)

Profound Medical has reported Receivables over the past 3 years, most recently at $7.3 million for Q4 2025.

  • Quarterly results put Receivables at $7.3 million for Q4 2025, down 1.02% from a year ago — trailing twelve months through Dec 2025 was $7.3 million (down 1.02% YoY), and the annual figure for FY2025 was $7.3 million, down 1.02%.
  • Receivables for Q4 2025 was $7.3 million at Profound Medical, down from $8.3 million in the prior quarter.
  • Over the last five years, Receivables for PROF hit a ceiling of $8.3 million in Q3 2025 and a floor of $3.2 million in Q4 2023.
  • Median Receivables over the past 3 years was $6.7 million (2025), compared with a mean of $6.1 million.
  • Biggest five-year swings in Receivables: soared 132.17% in 2024 and later fell 1.02% in 2025.
  • Profound Medical's Receivables stood at $3.2 million in 2023, then surged by 132.17% to $7.4 million in 2024, then fell by 1.02% to $7.3 million in 2025.
  • The last three reported values for Receivables were $7.3 million (Q4 2025), $8.3 million (Q3 2025), and $4.3 million (Q2 2025) per Business Quant data.